Analyst consensus rating
Context Therapeutics Analyst Rating: Strong Buy
CNTX is rated Strong Buy by 9 analysts with a $4.25 target. As of 2026-08-22.
Direct answer
Context Therapeutics's consensus rating is Strong Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $4.25.
Forecast evidence checked August 22, 2026.
Get free Context Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.50
- Average price target
- $4.25
- High price target
- $6.00
- Low price target
- $2.00
- Low target gap
- +299.9%
- Target upside
- +750.1%
- High target gap
- +1,099.8%
- Target range width
- 799.8%
- Consensus rating
- Strong Buy
- Analysts
- 9
- Evidence date
- August 22, 2026
- Valid through
- August 29, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Context Therapeutics?
Context Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $4.25.
How far are Context Therapeutics's low and high targets from the recorded price?
The low target implies +299.9%, while the high target implies +1,099.8%.
How many analysts are included in Context Therapeutics's consensus?
The verified consensus includes 9 analysts.
How is Context Therapeutics's target upside or downside calculated?
The average target of $4.25 is divided by the recorded price of $0.50, then one is subtracted to produce +750.1%. This does not guarantee a future return.
When was Context Therapeutics's analyst forecast verified?
The data was verified on 2026-08-22. The dataset is valid through 2026-08-29.